Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis

• Published in: European journal of gastroenterology & hepatology Vol. 28; no. 7; p. 777
• Main Authors: Salman, Tary A, Edrees, Ahmed M, El-Said, Hala H, El-Abd, Osama L, El-Azab, Gasser I
• Format: Journal Article
• Language: English
• Published: England 01.07.2016
• Subjects: Adult; Bacterial Infections - complications; Bacterial Infections - physiopathology; Drug Therapy, Combination; Female; Hemodynamics - drug effects; Hepatorenal Syndrome - etiology; Hepatorenal Syndrome - prevention & control; Humans; Liver Circulation - drug effects; Liver Cirrhosis - complications; Liver Cirrhosis - physiopathology; Lypressin - analogs & derivatives; Lypressin - therapeutic use; Male; Middle Aged; Midodrine - therapeutic use; Peritonitis - complications; Peritonitis - physiopathology; Renal Circulation - drug effects; Serum Albumin - therapeutic use; Treatment Outcome; Vasoconstrictor Agents - therapeutic use
• ISSN: 1473-5687
• DOI: 10.1097/MEG.0000000000000635

Spontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. Two hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. SBP resolved in most of patients in all groups (P>0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. Terlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.